Corealis Pharma Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
1
Corealis Pharma General Information
Description
Provider of contract manufacturing services of solid oral dosage (tablets, capsules and granules) intended to serve the pharmaceutical and biotech companies. The company offers formulation development and clinical supplies, thereby investing resources and efforts in ensuring that the drugs are developed to meet the client's needs.
Contact Information
Website
www.corealispharma.comCorporate Office
- 200, Armand Frappier Boulevard
- Laval, Quebec H7V 4A6
- Canada
Corporate Office
- 200, Armand Frappier Boulevard
- Laval, Quebec H7V 4A6
- Canada
Corealis Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Corealis Pharma Comparisons
Industry
Financing
Details
Corealis Pharma Competitors (19)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Axplora | Private Equity-Backed | Raubling, Germany | ||||
| Intellipharmaceutics International | Corporation | Toronto, Canada | ||||
| Acura Pharmaceuticals | Formerly VC-backed | Palatine, IL | ||||
| Talphera | Formerly VC-backed | San Mateo, CA | ||||
| Par Pharmaceutical Companies | Formerly PE-Backed | Woodcliff Lake, NJ |
Corealis Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Corealis Pharma Patents
Corealis Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230174493-A1 | Solid dispersions of amorphous 3,4-diphenyl-4,5-dihydro-1h-pyrazole derivatives, compositions comprising them and uses thereof as cannabinoid cb1 receptor inhibitors | Pending | 24-Mar-2020 | ||
| US-20170305843-A1 | Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto | Active | 26-Sep-2014 | ||
| US-10059660-B2 | Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto | Active | 26-Sep-2014 | ||
| US-9546135-B2 | Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto | Active | 26-Sep-2014 | ||
| US-20160090354-A1 | Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto | Active | 26-Sep-2014 | C07C275/28 |
Corealis Pharma Executive Team (5)
| Name | Title | Board Seat |
|---|---|---|
| Patrick Frankham | Chief Executive Officer | |
| Yves Roy Ph.D | Co-Founder & President | |
| Edith Lauzon | Director, Finance | |
| Yves Mouget Ph.D | Co-Founder & Vice President of Analytics | |
| Patrick Gosselin Ph.D | Co-Founder & Vice President of Pharmaceutical R&D |
Corealis Pharma Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Self | Board Member |
Corealis Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Corealis Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Corealis Pharma FAQs
-
When was Corealis Pharma founded?
Corealis Pharma was founded in 2005.
-
Who is the founder of Corealis Pharma?
Yves Roy Ph.D, Yves Mouget Ph.D, and Patrick Gosselin Ph.D are the founders of Corealis Pharma.
-
Who is the CEO of Corealis Pharma?
Patrick Frankham is the CEO of Corealis Pharma.
-
Where is Corealis Pharma headquartered?
Corealis Pharma is headquartered in Laval, Canada.
-
What is the size of Corealis Pharma?
Corealis Pharma has 50 total employees.
-
What industry is Corealis Pharma in?
Corealis Pharma’s primary industry is BPO/Outsource Services.
-
Is Corealis Pharma a private or public company?
Corealis Pharma is a Private company.
-
What is Corealis Pharma’s current revenue?
The current revenue for Corealis Pharma is .
-
Who are Corealis Pharma’s investors?
ARCHIMED and Caisse de dépôt et placement du Québec have invested in Corealis Pharma.
-
Who are Corealis Pharma’s competitors?
Axplora, Intellipharmaceutics International, Acura Pharmaceuticals, Talphera, and Par Pharmaceutical Companies are some of the 19 competitors of Corealis Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
